Latest News
Press Releases
-
CSC’S DVC Wins $32.3 Million NIAID Contract to Establish Phase 1 Clinical Trial Unit
Quintiles Transnational Teams to Provide Clinical Research and Support
FALLS CHURCH, Va., July 14 – CSC (NYSE: CSC) announced today that DynPort Vaccine Company LLC (DVC), a CSC company, has received a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to establish and operate a Phase 1 clinical trial unit for infectious disease therapeutics.
-
CSC’S DynPort Vaccine Company to Continue Plague Vaccine Development
FALLS CHURCH, Va., June 5 – CSC (NYSE: CSC) announced today that DynPort Vaccine Company LLC (DVC), a CSC company, has been notified by the Department of Defense (DoD) that all future funding for advanced development of plague vaccine will be allocated to the existing DVC contract with the Joint Project Manager Chemical, Biological and Medical Systems’ Joint Vaccine Acquisition Program (JVAP) Joint Product Management Office.
>More DVC press releases
News Articles
-
Biodefense Q&A Series with Dr. House: Part 2 - Biodefense Industry Trends
Dr. House discusses trends in government contracting and product development in the penultimate installment in this series. -
Biodefense Q&A Series with Dr. House: Part 1 - DVC and Biodefense
DVC president Dr. Robert V. House discusses biodefense industry challenges in the first of a three-part series. -
DVC Selected as Recipient of Gazette of Politics and Business First Exceptional 53 Business Award
DVC was recognized for its exceptional growth during the last three years as well as company-sponsored community service programs and innovation in managing biopharmaceutical product development programs.
>More DVC news articles
About DVC
Media Information
Media Contacts
|
Press inquiries only: |
Amanda Cecil |